Year: 2023

New_Bio-Thera_Logo

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase...

news_6

Hoffmann Green Cement Announces the Granting of the H-EVA Patent in China, its Clinker-Free Cement Based on Activated Clay

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Regulatory News: Hoffmann Green Cement Technologies (Paris:ALHGR) (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial...